title: Management of acute coronary syndromes with fondaparinux.
abstract: Fondaparinux is the first selective inhibitor of the coagulation factor Xa which is commercially avaliable for clinical use. It has been approved for the prevention of venous thromboembolism in patients undergoing orthopedic surgery and for the initial therapy of venous thromboembolism. In randomized clinical trials the value of fondaparinux in the treatment of ST-elevation myocardial infarction (STEMI) has been investigated. The PENTALYSE study showed that fondaparinux was at least as effective and safe as unfractionated heparin in 333 patients with STEMI undergoing fibrinolysis with t-PA. In the recent large OASIS-6 trial with 12,092 patients the treatment with 2.5 mg fondaparinux daily significantly reduced death and reinfarctions until day 30 compared with guideline recommended usual care and compared with unfractionated heparin (9.7% vs 11.2%, p = 0.008) without increasing major bleedings (1.0% vs 1.3%, p = 0.13). This advantage was predominantly seen in the subgroups of patients with fibrinolysis and without early reperfusion therapy. However, in the subgroup of primary percutaneous coronary interventions (PCIs) no clinical benefit of fondaparinux was found, but there were more catheter thrombosis and acute thrombotic complications. In summary, fondaparinux is a new antithrombin that is an efficient, safe, and easy to use in treatment for STEMI patients, particularly those not undergoing primary PCI.
authors: Herzzentrum Ludwigshafen, Medizinische Klinik B, Germany.
authors: Harm
authors: H
authors: Wienbergen
authors: Uwe
authors: U
authors: Zeymer
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy*; D000925:Anticoagulants / Q000494:pharmacology* / Q000627:therapeutic use; D000077425:Fondaparinux; D006493:Heparin / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D011134:Polysaccharides / Q000494:pharmacology* / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D020246:Venous Thrombosis / Q000188:drug therapy / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D011134:Polysaccharides; D006493:Heparin; D000077425:Fondaparinux
references: Eur Heart J. 2001 Sep;22(18):1716-24
references: 11511121
references: Arch Intern Med. 2002 Sep 9;162(16):1833-40
references: 12196081
references: J Am Coll Cardiol. 2004 Aug 4;44(3):671-719
references: 15358045
references: J Clin Pharmacol. 1992 Jul;32(7):584-96
references: 1322434
references: Am J Cardiol. 1998 Sep 10;82(5B):15L-18L
references: 9737475
references: CMAJ. 2006 May 9;174(10):1421-6
references: 16682709
references: Circulation. 2005 Mar 22;111(11):1390-7
references: 15781750
references: J Thromb Thrombolysis. 2006 Feb;21(1):67-72
references: 16475045
references: JAMA. 2006 Apr 5;295(13):1519-30
references: 16537725
references: N Engl J Med. 2006 Apr 6;354(14):1464-76
references: 16537663
references: N Engl J Med. 2006 Apr 6;354(14):1477-88
references: 16537665
references: Eur J Clin Invest. 2005 Mar;35 Suppl 1:27-32
references: 15701145